Abstracts tagged "Biologic drugs and psoriatic arthritis"

Abstract Number: 2623 • 2018 ACR/ARHP Annual Meeting
Efficacy of TNF Inhibitors and Predictive Factors of Clinical Presentation in Patients with Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia¹, Victoria Navarro-Compán², Borja Hernández-Breijo³, Alejandro Villalba¹, Diana Peiteado⁴, Elisa Fernández¹, Patricia Bogas⁵, Mercedes de Diego¹ and Alejandro Balsa⁵, ¹Rheumatology, La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Immunology, La Paz University Hospital, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneus disease. Patients with PsA may have predominant axial (axPsA) or peripheral (pPsA) manifestations but the factors influencing on…
Abstract Number: 1566 • 2014 ACR/ARHP Annual Meeting
The Efficacy and Safety of Biological Disease Modifying Anti-Rheumatic Drugs and Apremilast in the Treatment of Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Arthur N. Lau¹, Michael Zoratti², Alfred Cividino³, William Bensen³, Jonathan D. Adachi³ and Christopher Edwards⁴, ¹Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Clinical Epidemiology and Biostatistics, Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Background/Purpose Currently, there are a number of effective therapies for psoriatic arthritis (PsA). The objective of this systematic review was to assess the efficacy (PSARC,…
Abstract Number: 1542 • 2014 ACR/ARHP Annual Meeting
Predicting Successful Long-Term Treatment with Tumour Necrosis Factor-Alpha Inhibitors in Patients with Psoriatic Arthritis
Karen M. Fagerli^1,2, Kath D. Watson², Jonathon Packham³, Deborah PM Symmons^4,5, Kimme L. Hyrich⁶ and . On behalf of the BSRBR⁷, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ³Institute of Science and Technology in Medicine, Keele, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷British Society for Rheumatology, London, United Kingdom
Background/Purpose Short-term efficacy of tumour necrosis factor-alpha inhibitor (TNFi) therapy in patients with psoriatic arthritis (PsA) is well documented. In observational studies, effectiveness has mainly…
Abstract Number: 340 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics and Treatment Outcomes In Psoriasis Patients With Polyarthritis Or Oligoarthritis
Philip S. Helliwell¹, Philip Mease², Eustratios Bananis³, Heather Jones⁴, Annette Szumski³ and Lisa Marshall⁴, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Collegeville, PA
Background/Purpose: Most randomized control trials (RCTs) for psoriatic arthritis (PsA) include patients with asymmetric oligoarthritis (AO) and polyarthritis (PA). There are limited data from RCTs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].